Researchers track side effects of Blood-Clotting drug in haemophilia patients

NCT ID NCT04682145

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 25 times

Summary

This study gathers safety information from a European registry about the drug turoctocog alfa pegol, used to treat haemophilia A. Researchers will count and analyze side effects reported by patients already in the registry. No extra visits or tests are required from participants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HAEMOPHILIA A are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Novo Nordisk Investigational Site

    Søborg, 2860, Denmark

Conditions

Explore the condition pages connected to this study.